| First Posted | New Trial Filing | Phase | Status |
|---|---|---|---|
| 2026-05-29 | NCT07612774 CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS | Phase 4 | Recruiting |
| 2026-05-29 | NCT07614958 Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs… | Phase 3 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05641753 | Cholesterol Lowering and Residual Risk in Diabetes, Type 1 | Type 1 Diabetes | Recruiting |
| NCT07612774 | CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS | Coronary | Recruiting |
| NCT04951856 | Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction… | STEMI - ST Elevation Myocardial Infarction | Active, Not Recruiting |
| Phase 3 | |||
| NCT07219602 | A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or… | Lipidemia | Recruiting |
| NCT07614958 | Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs… | Mixed Dyslipidemia | Recruiting |
| NCT06305559 | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | Lipidemia | Active, Not Recruiting |
| Phase 2 | |||
| NCT06700720 | YN001-004 in Patients With Coronary Atherosclerosis in Australia | Coronary Artery Disease | Recruiting |
| NCT06496243 | Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | Dyslipidemias | Recruiting |
| NCT06284564 | A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With… | Metastatic Renal Cell Carcinoma | Active, Not Recruiting |
| Early Phase 1 | |||
| NCT06081153 | Mechanistic Clinical Trial of PCSK9 Inhibition for AAA | Abdominal Aortic Aneurysm | Not Yet Recruiting |
| Not specified | |||
| NCT07388420 | Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced… | Hypertriglyceridemia Induced Acute Pancreatitis | Recruiting |